{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:49:01Z","timestamp":1785160141692,"version":"3.55.0"},"reference-count":36,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/16893- 8"],"award-info":[{"award-number":["2018\/16893- 8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,6,19]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>There is limited information regarding the incidence of treatment-related adverse events (AE) following antiretroviral therapy (ART) in women. So, this review aimed to describe the incidence of AE of ART in women living with HIV\/AIDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Medline, Embase, Cochrane Library, Epistemonikos, Lilacs and Who Index, from inception to 9 April 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>We included randomised controlled trials with at least 12 weeks of follow-up and evaluated AE of ART in women at any age living with HIV\/AIDS, without restrictions on status, year or language of publication. We excluded post hoc or secondary analyses and open-label extensions without comparator, and trials involving pregnant or breastfeeding women or with a focus on coinfection with tuberculosis, hepatitis B or C. The primary outcomes were the incidence rate of participants with any clinical and\/or laboratory AE related or not to ART and treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two independent reviewers extracted data and assessed the risk of bias using Cochrane\u2019s risk of bias tool 2. We used Bayesian random-effects meta-analysis to summarise event rates. Results were presented as event rates per 1000 person-years (95% credibility intervals, 95% CrI). The pooled incidence rate per 1000 person-years adjusted for duration and loss to follow-up was estimated. We assessed the certainty of the evidence using Grading of Recommendations, Assessment, Development and Evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 24 339 studies were identified for screening, of which 10 studies (2871 women) met the eligibility criteria, with 11 different antiretrovirals (ARVs) regimens. Seven studies included exclusively women, while in the remaining three, the proportion of women ranged from 11% to 46%. Nine studies received industry funding. The pooled analysis showed a mean incidence rate of ART-related clinical and laboratory AE of 341.60 events per 1000 person-years (95% CrI 133.60\u2013862.70), treatment discontinuation of 20.78 events per 1000 person-years (95% CrI 5.58\u201357.31) and ART-related discontinuation of 4.31 per 1000 person-years (95% CrI 0.13\u201354.72). Summary estimates were subject to significant uncertainty due to the limited number of studies and sparse data. The certainty of the evidence was graded as very low for all outcomes assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Existing randomised trials do not provide sufficient evidence on the incidence rates of safety outcomes from antiretroviral treatment in women living with HIV\/AIDS. Large comparative studies in well-characterised populations are needed to provide a more comprehensive landscape of the safety profile of these ARV therapies in women with HIV\/AIDS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42021251051.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-079292","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:02:41Z","timestamp":1722470561000},"page":"e079292","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Rates of adverse events of antiretroviral therapy in women living with HIV\/AIDS: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct01705574","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00084136","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01910402","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00089505","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00089505","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02431247","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02652624","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01387022","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02269917","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-2787","authenticated-orcid":false,"given":"Jardel Corr\u00eaa","family":"de Oliveira","sequence":"first","affiliation":[{"name":"Graduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil"},{"name":"Primary Health Care Services and Family Medicine Residency Program, Florian\u00f3polis City Hall, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00edra Ramos","family":"Alves","sequence":"additional","affiliation":[{"name":"Graduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-110X","authenticated-orcid":false,"given":"Luis Phillipe Nagem","family":"Lopes","sequence":"additional","affiliation":[{"name":"Graduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-1130","authenticated-orcid":false,"given":"Fabiane Raquel","family":"Motter","sequence":"additional","affiliation":[{"name":"Graduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil"},{"name":"S\u00edrio-Liban\u00eas Hospital, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Suguimoto","family":"Iwami","sequence":"additional","affiliation":[{"name":"Nursing Undergraduate Course, University of Sorocaba, Sorocaba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane de C\u00e1ssia","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Graduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7186-9075","authenticated-orcid":false,"given":"Marcus Tolentino","family":"Silva","sequence":"additional","affiliation":[{"name":"Graduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Luis","family":"Scalco","sequence":"additional","affiliation":[{"name":"Primary Health Care Services and Family Medicine Residency Program, Florian\u00f3polis City Hall, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8434-9781","authenticated-orcid":false,"given":"Donavan de Souza","family":"Lucio","sequence":"additional","affiliation":[{"name":"Primary Health Care Services and Family Medicine Residency Program, Florian\u00f3polis City Hall, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Giustti","family":"Mazzei","sequence":"additional","affiliation":[{"name":"Department of Physiotherapy, University of Sorocaba, Sorocaba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo D\u2019Agostini","family":"Derech","sequence":"additional","affiliation":[{"name":"Florian\u00f3polis City Hall, Florian\u00f3polis, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Itria","sequence":"additional","affiliation":[{"name":"Department of Economics, Federal University of S\u00e3o Carlos, S\u00e3o Carlos, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Ot\u00e1vio Maia","family":"Barreto","sequence":"additional","affiliation":[{"name":"Fiocruz Brasilia, Oswaldo Cruz Foundation, Brasilia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3684-3275","authenticated-orcid":false,"given":"Luciane Cruz","family":"Lopes","sequence":"additional","affiliation":[{"name":"Graduate Course in Pharmaceutical Sciences, University of Sorocaba, Sorocaba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"2025121601051517000_14.7.e079292.1","unstructured":"UNAIDS . Global HIV & AIDS statistics \u2014 fact sheet, 2022. Available: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"2025121601051517000_14.7.e079292.2","unstructured":"Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia, Preven\u00e7\u00e3o e Controle das Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis, do HIV\/Aids e das Hepatites Virais . Protocolo cl\u00ednico e diretrizes terap\u00eauticas para manejo da infec\u00e7\u00e3o pelo HIV em adultos. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2018:412."},{"key":"2025121601051517000_14.7.e079292.3","unstructured":"European AIDS Clinical Society . Guidelines [Internet]. 2021. Available: https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf"},{"key":"2025121601051517000_14.7.e079292.4","unstructured":"National Institute of Health . Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2019. Available: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/initiation-antiretroviral-therapy"},{"key":"2025121601051517000_14.7.e079292.5","unstructured":"World Health Organization . Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2o edn.2016:480."},{"key":"2025121601051517000_14.7.e079292.6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","article-title":"A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies","volume":"71","author":"Curno","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025121601051517000_14.7.e079292.7","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.3.2.213"},{"key":"2025121601051517000_14.7.e079292.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226992","article-title":"High prevalence of abnormal menstruation among women living with HIV in Canada","volume":"14","author":"Valiaveettil","year":"2019","journal-title":"PLoS One"},{"key":"2025121601051517000_14.7.e079292.9","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2006.15.591"},{"key":"2025121601051517000_14.7.e079292.10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QAD.0000000000002084","article-title":"HIV and amenorrhea: a meta-analysis","volume":"33","author":"King","year":"2019","journal-title":"AIDS"},{"key":"2025121601051517000_14.7.e079292.11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/S0004-27302010000200008","article-title":"Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review","volume":"54","author":"Carvalho","year":"2010","journal-title":"Arq Bras Endocrinol Metab"},{"key":"2025121601051517000_14.7.e079292.12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1590\/1806-9282.64.05.469","article-title":"Are women living with HIV prone to osteoporosis in postmenopause? A systematic review","volume":"64","author":"Cezarino","year":"1992","journal-title":"Rev Assoc Med Bras"},{"key":"2025121601051517000_14.7.e079292.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057094","article-title":"Sex differences and adverse events of antiretrovirals in people living with HIV\/AIDS: a systematic review and meta-analysis protocol","volume":"12","author":"de Oliveira","year":"2022","journal-title":"BMJ Open"},{"key":"2025121601051517000_14.7.e079292.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025121601051517000_14.7.e079292.15","unstructured":"Covidence [Internet] . Covidence - better systematic review management. 2022. Available: https:\/\/www.covidence.org\/"},{"key":"2025121601051517000_14.7.e079292.16","unstructured":"Rayyan [internet]. n.d. Available: https:\/\/rayyan.ai\/reviews\/640676"},{"key":"2025121601051517000_14.7.e079292.17","unstructured":"Cochrane . Revised cochrane risk-of-bias tool for randomized trials (Rob 2). 2019."},{"key":"2025121601051517000_14.7.e079292.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"key":"2025121601051517000_14.7.e079292.19","unstructured":"Haddaway NR , McGuinness LA , Pritchard CC . PRISMA2020: R package and shinyapp for producing PRISMA 2020 compliant flow diagrams. Zenodo 2021. Available: https:\/\/zenodo.org\/record\/4287834"},{"key":"2025121601051517000_14.7.e079292.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001290","article-title":"Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings","volume":"9","author":"Campbell","year":"2012","journal-title":"PLoS Med"},{"key":"2025121601051517000_14.7.e079292.21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1179\/1528433614Z.0000000013","article-title":"Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial","volume":"16","author":"Firnhaber","year":"2015","journal-title":"HIV Clin Trials"},{"key":"2025121601051517000_14.7.e079292.22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","article-title":"A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","volume":"32","author":"Eron","year":"2018","journal-title":"AIDS"},{"key":"2025121601051517000_14.7.e079292.23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/15284336.2019.1608714","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-na\u00efve patients with HIV-1: subgroup analyses of the phase 3 AMBER study","volume":"20","author":"Rashbaum","year":"2019","journal-title":"HIV Res Clin Pract"},{"key":"2025121601051517000_14.7.e079292.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906626"},{"key":"2025121601051517000_14.7.e079292.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001236","article-title":"Nevirapine- versus lopinavir\/ritonavir-based initial therapy for HIV-1 infection among women in africa: a randomized trial","volume":"9","author":"Lockman","year":"2012","journal-title":"PLoS Med"},{"key":"2025121601051517000_14.7.e079292.26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3851\/IMP3106","article-title":"Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials","volume":"22","author":"Naicker","year":"2017","journal-title":"Antivir Ther"},{"key":"2025121601051517000_14.7.e079292.27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hiv.12961","article-title":"Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF\/FTC\/NNRTI to ABC\/3TC\/DTG","volume":"22","author":"Ibrahim","year":"2021","journal-title":"HIV Med"},{"key":"2025121601051517000_14.7.e079292.28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial","volume":"82","author":"Kityo","year":"2019","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"2025121601051517000_14.7.e079292.29","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S2352-3018(17)30095-4","article-title":"Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study","volume":"4","author":"Orrell","year":"2017","journal-title":"Lancet HIV"},{"key":"2025121601051517000_14.7.e079292.30","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3018(16)30016-9","article-title":"Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study","volume":"3","author":"Squires","year":"2016","journal-title":"Lancet HIV"},{"key":"2025121601051517000_14.7.e079292.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12981-019-0235-1","article-title":"Darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study","volume":"16","author":"Huhn","year":"2019","journal-title":"AIDS Res Ther"},{"key":"2025121601051517000_14.7.e079292.32","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.306"},{"key":"2025121601051517000_14.7.e079292.33","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15284336.2016.1243363","article-title":"Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection","volume":"17","author":"Bedimo","year":"2016","journal-title":"HIV Clin Trials"},{"key":"2025121601051517000_14.7.e079292.34","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32831db232"},{"key":"2025121601051517000_14.7.e079292.35","doi-asserted-by":"publisher","DOI":"10.1310\/hct1306-308"},{"key":"2025121601051517000_14.7.e079292.36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1590\/S0102-311X2003000400039","article-title":"Ensaios cl\u00ednicos pragm\u00e1ticos: uma op\u00e7\u00e3o na constru\u00e7\u00e3o de evid\u00eancias em sa\u00fade","volume":"19","author":"Coutinho","year":"2003","journal-title":"Cad Sa\u00fade P\u00fablica"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-079292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:05:34Z","timestamp":1765875934000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-079292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/bmjopen-2023-079292"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-079292","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}